Bristol-Myers Squibb vs Honda: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Honda was founded in 1948 by Soichiro Honda, Takeo Fujisawa and is led by Toshihiro Mibe.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Honda
- Founded
- 1948
- Headquarters
- Tokyo, Japan
- Current CEO
- Toshihiro Mibe
- Employees
- 195,109
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Honda
Soichiro Honda
Soichiro Honda founded the company in 1946. Originally a mechanic who manufactured piston rings for Toyota, he realized that post-war Japan desperately needed cheap, reliable transportation.
Takeo Fujisawa
Takeo Fujisawa co-founded Honda in 1949, serving as the absolute perfect business counterpart to Soichiro Honda's engineering obsession.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Honda
- Takanobu Ito2009–2015
President and CEO
He introduced a plan to reorganise Honda global operations and handed the presidency to Takahiro Hachigo in 2015.
Source - Takahiro Hachigo2015–2021
Former President and CEO
Hachigo trimmed excess capacity and refocused Honda on hybrids, motorcycles and its core models, which improved profitability before the EV investment cycle began.
Source - Toshihiro Mibe2021–present
Director, President and Representative Executive Officer (CEO)
Mibe's tenure has been defined by the push into electrification and its costly reset. The EV charges produced Honda's first annual loss since listing, but the shift toward hybrids and motorcycles was followed by a record first-quarter profit in FY2027.
Source
Timeline: Bristol-Myers Squibb and Honda side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1948Honda
Honda Motor Founded
Soichiro Honda establishes Honda Motor Co., Ltd. in Japan.
1959Honda
American Honda Opens
Honda enters the US market, initially building awareness through motorcycles.
1963Honda
Honda Enters Automobiles
Honda expands from motorcycles and engines into automobile production.
1972Honda
Civic Launch
The Civic becomes a defining global nameplate for Honda's fuel-efficient automobile strategy.
1986Honda
Acquired Montesa
Honda Motor Co. acquired Montesa. Honda took control of the Spanish motorcycle maker Montesa, creating Montesa Honda to build trial and off-road motorcycles in Europe.
1986Honda
Acura Brand Launched
Honda launched the Acura luxury brand in the United States in 1986.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
2000Honda
ASIMO Unveiled
Honda unveiled the ASIMO humanoid robot in 2000.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2015Honda
Takahiro Hachigo becomes CEO
Takahiro Hachigo became CEO of Honda Motor Co. in 2015. Hachigo trimmed excess capacity and refocused Honda on hybrids, motorcycles and its core models, which improved profitability before the EV investment cycle began.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2021Honda
Toshihiro Mibe Becomes CEO
Mibe becomes CEO as Honda increases focus on electrification, software, and new mobility.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Honda
FY2026 Loss and EV Reset
Honda reports ~$146 billion (JPY 21.797 trillion) in sales revenue and a ~$2.84 billion (JPY 423.9 billion) loss attributable to owners after EV write-downs, then posts a record ~$3.56 billion (JPY 530.7 billion) Q1 FY2027 operating profit in August.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Questions about Bristol-Myers Squibb vs Honda
Who is the CEO of Bristol-Myers Squibb Company and Honda Motor Co., Ltd.?
Bristol-Myers Squibb Company is led by Christopher Boerner and Honda Motor Co., Ltd. is led by Toshihiro Mibe. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Honda Motor Co., Ltd.?
Bristol-Myers Squibb Company was founded in 1887 — 61 years before Honda Motor Co., Ltd., which was founded in 1948. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Honda Motor Co., Ltd..
How many employees does Bristol-Myers Squibb Company have compared to Honda Motor Co., Ltd.?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Honda Motor Co., Ltd. employs approximately 195,109. Honda Motor Co., Ltd. has the larger workforce at 195,109 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Honda Motor Co., Ltd. headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Honda Motor Co., Ltd. is headquartered in Japan. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Honda Motor Co., Ltd.?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Honda Motor Co., Ltd. was founded by Soichiro Honda, Takeo Fujisawa.
Which company has a longer operating history — Bristol-Myers Squibb Company or Honda Motor Co., Ltd.?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Honda Motor Co., Ltd. has been in operation for around 78 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Honda overview